Lexeo Therapeutics (LXEO) Accounts Payables (2022 - 2026)
Lexeo Therapeutics (LXEO) posted Accounts Payables of $3.3 million for Q1 2026, down 31.32% sequentially from $4.9 million in Q4 2025, and down 72.16% YoY from $12.0 million in Q1 2025.
Lexeo Therapeutics (LXEO) Accounts Payables (2022 - 2026) Analysis & Trends
Lexeo Therapeutics has reported Accounts Payables for 5 years, with the latest figure at $3.3 million in Q1 2026.
- Quarterly Accounts Payables fell 72.16% year-over-year to $3.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.3 million (down 72.16% YoY) and the FY2025 annual result came in at $4.9 million, down 24.33% from the prior year.
- Accounts Payables retreated to $3.3 million in Q1 2026 per LXEO's latest filing, from $4.9 million in the prior quarter.
- Over five years, Accounts Payables peaked at $20.0 million in Q2 2025 and troughed at $2.7 million in Q3 2023.
- A 5-year average of $6.6 million and a median of $4.8 million in 2025 frame the typical range for Accounts Payables.
- The sharpest annual moves came in 2025 and 2026: Accounts Payables surged 247.35% in 2025, then sank 72.16% in 2026.
- Over 5 years, Accounts Payables stood at $2.7 million in 2022, then soared by 41.67% to $3.8 million in 2023, then jumped by 69.14% to $6.4 million in 2024, then fell by 24.33% to $4.9 million in 2025, then slumped by 31.32% to $3.3 million in 2026.
- According to Business Quant data, Accounts Payables over the past three periods registered $3.3 million, $4.9 million, and $4.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Lexeo Therapeutics | 397.10 Mn | 397.10 Mn | - | 4.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.18 Mn |
| Mar 31, 2026 | 3.34 Mn |
| Dec 31, 2025 | 4.86 Mn |
| Sep 30, 2025 | 4.66 Mn |
| Jun 30, 2025 | 20.03 Mn |
| Mar 31, 2025 | 11.98 Mn |
| Dec 31, 2024 | 6.42 Mn |
| Sep 30, 2024 | 8.44 Mn |
| Jun 30, 2024 | 5.77 Mn |
| Mar 31, 2024 | 4.30 Mn |
| Dec 31, 2023 | 3.79 Mn |
| Sep 30, 2023 | 2.66 Mn |
| Dec 31, 2022 | 2.68 Mn |